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Ischemic stroke during pregnancy and puerperium represents a rare occurrence but it could be a serious and stressful event for
mothers, infants, and also families. Whenever it does occur, many concerns arise about the safety of the mother and the fetus
in relation to common diagnostic tests and therapies leading to a more conservative approach. The physiological adaptations in
the cardiovascular system and in the coagulability that accompany the pregnant state, which are more signiﬁcant around delivery
and in the postpartum period, likely contribute to increasing the risk of an ischemic stroke. Most of the causes of an ischemic
strokein the young may alsooccur in pregnant patients. Despite this,there are speciﬁc conditions related to pregnancy which may
be considered when assessing this particular group of patients such as pre-eclampsia-eclampsia, choriocarcinoma, peripartum
cardiomiopathy, amniotic ﬂuid embolization, and postpartum cerebral angiopathy. This article will consider several questions
related to pregnancy-associated ischemic stroke, dwelling on epidemiological and speciﬁc etiological aspects, diagnostic issue
concerning the use of neuroimaging, and the related potential risks to the embryo and fetus. Therapeutic issues surrounding the
useofanticoagulantandantiplateletsagentswillbediscussedalongwiththefewavailablereports regardingtheuseofthrombolytic
therapy during pregnancy.
1.Introduction
Ischemic stroke is more common in men than in women
until advanced age, when a higher incidence is observed in
women [1]. When younger patients are considered, females
usually exceed males under 35, a period that coincides
with the prime child-bearing years [2, 3]. Pregnancy and
puerperium may partly contribute to this increased rate.
Ischemic stroke during pregnancy is a rare occurrence
but it could be a serious and stressful event for mothers,
infants, and also their families.
Aconservative approach isfrequentlyadoptedbecauseof
concerns of any adverse eﬀects of treatment and etiological
investigations on the mother and the unborn fetus.
This article describes the physiological changes that may
increase the risk of cerebral complications and deepens
speciﬁc mechanisms, risk factors for ischemic stroke, and
management of this subgroup of patients.
2.Maternal ChangesduringPregnancy
Predisposing to Ischemic Stroke
Maternal physiological alterations occur during pregnancy
as a consequence of the variations of the hormonal sta-
tus, involving the haemostatic and hemodynamic systems.
Wether this adaptation could aﬀect the risk of an ischemic
stroke is still unclear and the relationship is likely complex.
2.1. Haemostatic Adaptations. Pregnancy is normally asso-
ciated with signiﬁcant changes in venous ﬂow and in the
molecular mediators of haemostasis, to the extent that the
overall balance shifts towards a hypercoagulant eﬀect [4]
(Table 1).
Procoagulant changes are more marked around termand
in the immediate postpartum period, presumably related to
the expulsion of the placenta and release of thromboplastic2 Stroke Research and Treatment
Table 1: Modiﬁcations of haemostatic factors during pregnancy.
Procoagulant factors
Fibrinogen (factor I) ↑
von Willebrand factor ↑
Factors VII, VIII, IX, X, XII ↑
Factors V, XIII ↑↓
Factor XI C
Factor II C
Coagulation inhibitors
Protein S ↓
Protein C, antithrombin III =
Fibrinolytic factors
Tissue plasminogenactivator ↓
Plasminogenactivator inhibitor 1 and 2 (PAI-1, PAI-2) ↑
Thrombin activatable ﬁbrinolysis inhibitor (TAFI) ↑
Others
Platelet count ↓
Prothrombin fragment 1+2 ↑
Thrombin-antithrombin complex ↑
D-dimer, ﬁbrinopeptide-A ↑
↑:i n c r e a s e ;↓: decrease; =: no signiﬁcant change; ↑↓: early increase followed
b yd e c r e a s e ;C :c o n t r o v e r s i a ld a t a .
substances at the site of separation. Blood coagulation and
ﬁbrinolysis get back to those of the nonpregnant state
approximately 3 weeks after delivery [4].
This resulting hypercoagulable state in association with a
venous stasis condition may likely account for an increased
risk of thromboembolic complications, in particular, during
the third trimester and the puerperium.
2.2. Hemodynamic Adaptations. In the ﬁrst 10 weeks of
pregnancy, a volume shifting develops with an increase of
total body water, that remains stably increased until 1 to
2 weeks after delivery, after which it gradually returns to
normal.
This hypervolemic state combined with an increasing
circulatory demands of fetus and placenta results in a rise
of 30% to 50% of cardiac output, stroke volume, and heart
rate. Half of this change occurs during the ﬁrst 8 weeks of
pregnancy, reaching a peak at 25–30 weeks. During labour,
there is a dramatic change in cardiac output which increases
progressively as labour advances increasing by a mean value
of 30%. Heart rate also increased consistently.
Then, in the ﬁrst days after delivery, there is a strong fall
of stroke volume and heart rate and cardiac outputgradually
decreases to 50% above prepregnancy level within 2 weeks
after delivery and returns to normal by 6 to 12 weeks [5].
As a consequence of decrease in systemic vascular resist-
ance,bloodpressure startstoloweraround theseventhweek,
hits the lowest levels at 24 to 32 weeks, and then increases
progressively to prepregnancy levels at term.
Venous compliance increases throughout pregnancy,
leading to decreased blood ﬂow, increased stasis, and a
tendency toward orthostatic pressure drops.
Aremodellinginarterial compositionwithareductionin
collagen and elastin contents and a loss of distensibility that
partially normalizes near termhas beenalso observed during
pregnancy [6].
3.Epidemiology
In hospital-based and community-based reports, the inci-
dence for ischemic strokes associated with pregnancy or
puerperium varies considerably raging from 4.3 to 210 per
100,000 deliveries [7].
Potential explanations for this variability are: (1) dif-
ferences in study designs, (2) small sample size of most
studies, (3) inadequate consideration of referral bias, and
(4) diﬀerent deﬁnitions of strokes and stroke subtypes.
Studies are also not uniform in deﬁnition of postpartum
period. Moreover, estimation of incidence is inﬂuenced by
those studies reported before neuroimaging use became
widely available [8, 9]. When data published since 1985 are
considered [7, 9–16], the incidence rates is reduced ranging
from 4 to 41 per 100,000 pregnancies and decreases more
considering only the three population-based studies, with a
range from 4 to 11 cases per 100,000 deliveries [7, 9, 12]
(Table 2).
The risk of stroke varies according to pregnancy stages.
Kittner and coworkers estimated a relative risk of cerebral
infarction of 0.7 (95% CI, 0.3 to 1.6) during pregnancy,
which increased to 5.4 (95% CI, 2.9 to 10.0) during the six
weeks after pregnancy (after a live birth or stillbirth) [12]. In
hospital–based series, the frequency of ischemic stroke has
beenobserved to be higher inthe third trimester, with a peak
in the ﬁrst postpartum week [7, 14, 15].
In a large Swedish cohort of over 650,000 women with
over 1 million deliveries in an eight-year time period, the
greatest risk of ischemic and hemorrhagic stroke was found
around delivery [33,8 (95% CI 10.5 to 84.0), two days before
and one day after with an increased but declining risk over
the subsequent six weeks [8.3 (95% CI, 4.4 to 14.8] [17].
The reason of a clustering of events around delivery and
postpartum period is not clear but implies a possible link
with the coagulationproﬁle of thisstage. The large reduction
of blood volume or the rapid hormonal changes following
delivery have also been suggested to inﬂuence this stroke
risktiming,perhapsthroughhemodynamic,coagulative,and
vessel-wall changes [12].
4.RiskFactorsandAssociated Conditions
Data from the Nationwide Inpatient Sample in United States
for the period from 2000 to 2001 showed that several
medical conditions resulted associated with stroke in preg-
nancy such as hypertension, diabetes, heart disease, sickle
cell disease, anemia, thrombocytopenia, and thrombophilia.
Among lifestyle factors, alcohol, smoking, and substance
abuse were found to be signiﬁcantly associated to stroke in
pregnancy [18]. Pregnancy and delivery complications such
as infection, transfusion, postpartum hemorrhage, and ﬂuidStroke Research and Treatment 3
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and electrolyte imbalance were also linked to pregnancy-
related stroke [18]. However, this study was limited to data
derived from discharge record abstraction and no precise
information on stroke ischemic subtype were available.
Although the risk of pregnancy-related stroke is resulted
to be higher among women aged 35 years and older
[18], ischemic subtype has been associated with a younger
maternalage[12]andameanageunder30hasbeenreported
in patients with pregnancy-related stroke in hospital-based
series (Table 3).
Migraine headaches have been associated with a 17-fold
increased risk of stroke in pregnancy [18], a relation which is
stronger with ischemic subtype (OR 30.7, 17.4 to 34.1) [19].
However, diﬃculties in diﬀerentiating between migraine as a
manifestation or as a consequence of an ischemic stroke and
othersconditions suchas severepre-eclampsia, and migraine
as an independent risk factor for ischemic stroke during
pregnancy, limit the external validity of these ﬁndings.
Caesarean delivery has been shown to be associated with
a 3–12 times increased risk of peripartum and postpartum
stroke [20, 21]. Ischemic stroke risk was found to be
signiﬁcantly increased in women with Cesarean delivery and
up to 6 months postpartum [22]. However, an increased
number of caesarean delivery among patients with previous
stroke or with conditions that can increase the risk of
stroke such as preeclampsia-eclampsia may confound this
association.
5.EtiologyofIschemic StrokeinPregnancy
As several causes of ischemic stroke in the young have been
reported in pregnancy and the puerperium [23], in most
c a s e si ti sq u i t ed i ﬃcult to distinguish whether pregnancy is
coincidental or plays a role in the occurrence of the cerebral
infarction. Notwithstanding, there are speciﬁc conditions
related to pregnancy which may lead to ischemic stroke such
as preeclampsia and eclampsia, and most rare disorders such
as choriocarcinoma, amniotic ﬂuid embolism, peripartum
cardiomyopathy, and postpartum cerebral angiopathy. Since
most studiesincludedsmall numbers ofpatientsand authors
deﬁned strokes and stroke etiologies diﬀerently, a compar-
ison of the conditions that contribute to ischemic stroke
in pregnancy is limited. However, while a high proportion
of cases, ranging from 28% to 46%, has resulted to be
undetermined, preeclampsia-eclampsia and cardioembolic
causes represent the conditions that mainly contribute to
ischemic stroke (Table 3).
6.Pregnancy-SpeciﬁcCausesofIschemicStroke
6.1. Preeclampsia and Eclampsia. Preeclampsia-eclampsia,
a l s ok n o w na st o x e m i a ,i sam u l t isystem disorder that occurs
in the later stages of pregnancy and in the ﬁrst 6 to 8 weeks
after delivery, accounting for a substantial maternal and
perinatal mortality [24].
Pre-eclampsia is characterized by the presence of ele-
vated gestational blood pressure, proteinuria, and oedema.
Although this condition is usually asymptomatic, patients
may complain ofheadaches, visual abnormalities, confusion,
and impairment of consciousness. The onset of seizures or
coma deﬁnes eclampsia [24]. About 2% to 12% of patients
with eclampsia develop a HELLP syndrome [25], a life-
threatening condition characterized by hemolytic anemia
(H),elevatedliverenzymes(EL),andlowplateletcount(LP).
Preeclampsia occurs in about 6% to 8% of all pregnancies,
whereas eclampsia has an incidence of 1/1000 to 1/2000
deliveries in the United States [26].
Preeclampsia-eclampsia increases the risk of stroke [12,
22, 27]. The proportion of patients with ischemic stroke
related to preeclampsia-eclampsia during pregnancies varies
from 6% to 47% (Table 3). Moreover, preeclampsia is also
founded to increase the risk of stroke later in life suggesting
that these patients may be closely monitored and controlled
for stroke risk factors also beyond the postpartum period
[27].
Patients with severe pre-eclampsia or eclampsia may
manifest focal neurological deﬁcits, consistent with a clinical
diagnosis of stroke and on neuroimaging both ischemic or
hemorrhagic stroke may be found.
Clinical signs and neuroradiological lesions frequently
reverse completely within a few days or weeks. Brain com-
puted tomography (CT) and magnetic resonance imaging
(MRI) show subcortical white matter lesions often with
posterior predominanceand, toalesser extent,in thecortical
grey matter predominantly aﬀecting the parietooccipital
region, consistent with the presence of reversible vasogenic
edema. The appearance of cerebral edema on brain imaging
is thought to be the consequence of disturbed cerebral
autoregulation with cerebral endothelial leakage in the
setting of severe hypertension. These ﬁndings are similar
to those found in other vasculopathies associated to pre-
eclampsia such as the posterior reversible encephalopathy
syndrome (PRES).MRangiographymayalsoshowreversible
vasospasm of the large and medium-sized vessels.
The pathogenesis is complex and not completely under-
stood. This condition is characterized by abnormal vascular
response to placentation and by endothelial cell dysfunction
which represents common response leading to instability
of vascular tone with vasospasm in various organs and
activation of the coagulation system with microthrombi
formation [24, 28, 29] with the consequence of ischemic
damage in many organs.
The management of pre-eclampsia is aimed at delivery
of the fetus and placenta and drug therapy of hypertension.
Magnesium sulphate should be used for the treatment of
seizures and in prophylaxis may prevent or reduce the rate
of eclampsia and its complications in pre-eclamptic patients
[24, 30].
6.2. Choriocarcinoma. Choriocarcinoma is a malignant neo-
plasm that arises from placental trophoblastic tissue, usually
followingamolarpregnancybutalsotermdelivery,abortion,
and ectopicpregnancy. Ithas a tendencyto early metastasize,
especially to the lungs, brain, liver, and vagina [31]. Brain
metastases are relatively common complication involving
about one-ﬁfth of patients. The clinical presentation of
cerebral involvement includes headache, focal neurologicalStroke Research and Treatment 5
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deﬁcits, seizures, encephalopathy, signs of elevated intracra-
nial pressure, and excessively elevated serum β human
choriogonadotrophic hormone level [32, 33].
Choriocarcinoma is a highly vascular tumor and is
extremely prone to hemorrhage. In the brain, trophoblasts
may invade blood vessels, just as they would in the uterus.
Cerebral ischemic damage may be the result of thrombotic
process in damaged vessels or consequence of trophoblastic
cerebrovascular embolism [23].
6.3. Amniotic Fluid Embolism. Amniotic ﬂuid embolism
(AFE) is a rare complication of pregnancy, related more
frequently to advanced age and multiparity. AFE occurs
in the setting of a disrupted barrier between the amniotic
ﬂuid and maternal circulation. Why this entry into maternal
circulation occurs in some women and not in others is not
clearly understood.
The mortality rate varies from 61 to 86% and accounts
for approximately 10% of all maternal deaths in the United
States [34]. AFE usually presents at term during labour and
should be suspected in any pregnant patient, speciﬁcally
those with ruptured membranes, who develop sudden
onset dyspnea with hypoxia, acute hypotension, and/or
cardiac arrest followed by a profound coagulopathy; al a r g e
percentage of survivors has a permanent hypoxia-induced
neurological damage [34]. Paradoxical cerebral amniotic
ﬂuid embolism is possible [23]. Seizures is present in 10%–
20% of cases and may be at times the ﬁrst manifestation.
6.4. Postpartum Cerebral Angiopathy. Postpartum cerebral
angiopathy is characterized by prolonged but reversible
vasoconstriction of the cerebral arteries, usually associated
with acute onset, severe, recurrent headaches, with or
without additional neurologic signs and symptoms. It has
been described using various labels, including postpartum
angiopathy [35, 36], postpartum angiitis [37], and puerperal
cerebral vasospasm [38]. Although the pathophysiology is
scarcely understood, a disturbance in the control of cerebral
vascular tone seems to be a critical element, features similar
to those observed in preeclampsia or eclampsia [39]. Most
patients have a history of uncomplicated pregnancy and
normal labor and delivery, followed within days to a few
weeks by acute onset of headache with or without various
neurologic signs and symptoms. The brain MRI in patients
with postpartum angiopathy may show areas of T2/FLAIR
hyperintensity in any location, but especially in watershed
areas between vascular territories. Multifocal segmental
narrowing of large and medium-sized cerebral arteries
may be present on both magnetic resonance angiography
(MRA) and CT angiography. Arterial abnormalities are
better visualized with CT angiography and conventional
invasive catheter angiography; both of which require the use
of iodinated contrast material. The MRI and MRA features
may normalize with time, although extensive infarction may
develop [36].
6.5. Peripartum Cardiomyopathy. Peripartum cardiomyopa-
thy is a rare dilating cardiomyopathy, that develops in the
last gestational month of pregnancy or in the ﬁrst 5 months
after delivery, with no identiﬁable cause for heart failure
and in the absence of heart disease. Early development of a
cardiomyopathy during pregnancy has also been described
with similar clinical presentation and maternal outcome but
withahigherincidenceintwinpregnancies, shorterduration
of pregnancy, and lower birth weight [40].
The true incidence of this condition is unknown; the
reported rate is of 1 in 3000 to 1 in 4000 live births in the
United States but there are geographical diﬀerences being
rare in Europe and more common in Africa [41–43].
Risk factors include advanced age (>30 years), multi-
parity, obesity, twin pregnancies, preeclampsia, and severe
hypertension during pregnancy [40, 44, 45]. The etiology
remains uncertain. Suggested hypotheses include myocardi-
tis, abnormal immune response to pregnancy, maladaptive
response to the hemodynamic stresses of pregnancy, stress
activated cytokines, viral infection, and prolonged tocolysis.
Clinical features consist of heart failure with dilated
cardiac cavities. However, the diagnosis remains a challenge
because many normal women in the last month of a
normal pregnancy experience dyspnea, fatigue, and pedal
edema, symptoms similar to early congestive cardiac failure.
Peripartum cardiomyopathy is a diagnosis of exclusion,
distinguished by rapid onset, occurrence in the peripartum
period,and signiﬁcantimprovementinupto50%ofaﬀected
women.
Systemic and pulmonary embolization is frequently
associated with this condition with an estimated incidence
ranging from 25% to 40% [23]. Neurologic deﬁcits caused
bythromboembolism canrarely bethe presentingsymptoms
[46–48]. The incidence of ischemic stroke is about 5% [23].
Additionally, cerebral infarction may result more rarely from
cerebral hypoperfusion secondary to cardiac failure [49].
Prognosis is dependent on recovery of systolic function. The
majority of patients recover partially or completely but the
mortality rate is high and the rate of heart transplantation is
about11% [50].Recurrencesduring subsequentpregnancies
are common.
7. Brain Imaging Ischemic
StrokeduringPregnancy
Imaging studies as part of the workup should be based
on neurological indications but several concerns about fetal
exposure to radiation arise for the clinician. The harmful
eﬀects of radiation depend on the stage of gestation at which
the fetusisexposed, the totaldose ofradiationabsorbed, and
t h er a t ea tw h i c ht h ed o s ei sa b s o r b e d[ 51]. Fetal exposure to
ionizing radiation from CT ofthe maternal head is extremely
low.Potentialriskofbirthdefectsduetoradiationarelimited
to the ﬁrst few weeks, the embryogenesis period, when
the patient may not be aware of the pregnancy. Radiation-
protection precautions for the developing fetus should be
used whenever the question of pregnancy arises.
A CT perfusion study should be avoided due to a
signiﬁcant increaseoftheX-rayexposureandtothenecessity8 Stroke Research and Treatment
ofadministering intravenouscontrastunlesstheinformation
is critical to guide therapy. The use of iodinated contrast
material during pregnancy may pose some risk to the fetus.
There are no evidence of adverse fetal eﬀects in humans
to the magnetic ﬁeld exposure for magnetic resonance
imaging (MRI). It has been hypothesized that some risk
for the fetus may raise due to exposure to very powerful
magnetic ﬁelds, minimal increases in body temperature, and
loud tapping noises of the coils [52]. Although a possible
teratogenic eﬀect has been found in some studies on animal
models [53, 54], MRI is the preferred imaging option in
pregnancy.
Regarding the use of gadoliniumduring MRI study, toxic
eﬀects are not known but depositions of the gadolinium
ions in fetal tissue raises concerns. Moreover, animal repro-
duction studies showed that gadolinium at high dose have
teratogenic eﬀects [52, 55]. Therefore, the use of gadolinium
should be avoided in a pregnant woman unless speciﬁcally
indicated in particular situation where the decision must be
made after a well-documented and thoughtful risk-beneﬁt
analysis [56, 57].
8.Treatmentof Ischemic
StrokeduringPregnancy
The choice of therapy for an ischemic stroke in pregnancy
is complicated by potentials of fetal toxicity, in particular
during the ﬁrst trimester when the risk of teratogenicity
is the highest. Therapeutic intervention is inﬂuenced by
the identiﬁcation of underlying etiology and the related
eﬀectiveness of the treatment, the possibility of adverse
outcomes both to the mother and the fetus, and by the
consideration of the term of pregnancy.
8.1. Prevention Treatment. Therapeutic decision is made
diﬃcult by the lack of randomized controlled trials that
adequately compare treatment options for this group of
patients. Therefore, the choice of agents for prophylactic
strategies is largely based upon inferences from others
studies,primarily onpreventionofdeepveinthrombosisand
the use of anticoagulants in women with high-risk cardiac
conditions.
According to the American Heart Association (AHA)
guidelines for pregnant women with ischemic stroke or
TIA and high-risk thromboembolic conditions such as
coagulopathy and mechanical heart valves, three possible
therapeutic alternatives may be considered: (a) adjusted-
dose unfractionated heparin (UFH) throughout pregnancy,
(b) adjusted-dose low molecular weight heparins (LMWHs)
throughout pregnancy, (c) either UFH or adjusted-dose
LMWHs until week 13, then restarted from the middle
of the third trimester until delivery and warfarin at other
times [58]. For lower risk conditions, either UFH or LMWH
therapy is recommended in the ﬁrst trimester, followed by
lowdose of aspirin for the remainder of the pregnancy [58].
8.2. Anticoagulant Treatment. UFH and LMWH do not have
teratogenic eﬀects since they do not cross the placenta
and are not causes of fetal hemorrhage, although bleeding
at the utero-placental junction is possible. Several studies
strongly suggest that UFH/LMWH therapy is safe for the
fetus [59–62]. By contrast, warfarin cross the placenta and
can cause bleeding and malformation in the fetus [61, 63].
This agent is probable safe if administered during the ﬁrst 6
weeks of gestation, butconfers a risk ofembryopathy if given
between6weeksand12weeksofgestation[63].Inaddiction,
warfarin cause an anticoagulant eﬀect in the fetus, which
is a concern, particularly at the time of delivery, when the
combinationwith thetrauma ofdeliverycanleadtobleeding
in the neonate. Therefore, warfarin is best avoided during
pregnancy.
A major bleeding was reported in about 2% of the
pregnant women treated with UFH [62], which is consistent
with the observed rate in nonpregnant women receiving
UFH and warfarin therapy. Since the possibility of a
persistent anticoagulant eﬀect (for up to 28 hours after the
last injection of heparin), the use of UFH prior to labor
may complicate the delivery increasing the risk of bleeding
and contraindicates epidural analgesia. By contrast, LMWH
therapy is rarely related with bleeding complications and in
particular, it is not associated with an increased risk of severe
peripartum bleeding [64]. LMWH has also the advantages
of producing a more stable coagulant response and lower
incidence of osteoporosis. In about 3% of non pregnant
patients, the UFH therapy can cause the development of
the heparin-induced thrombocytopenia (HIT), an acquired
immuneconditionIgGmediated,whichisfrequentlycompli-
cated by extension ofthe preexisting thrombotic phenomena
or new arterial thrombosis [60]. In pregnant women who
developed HIT and require ongoing anticoagulant therapy,
use of the heparinoid danaparoid sodium is recommended
because it is aneﬀectiveantithrombotic agent,doesnot cross
the placenta, and has much less cross-reactivity with UFH
and, therefore, less potential to produce recurrent HIT than
LMWH [65].
Heparin and LMWHs do not reach the maternal milk
and can be safely given to nursing mothers [65]. The use of
warfarin is also safe during breastfeeding [65].
8.3. Antiplatelet Treatment. Wether treatment with aspirin
during the ﬁrst trimester of pregnancy is safe remains
unclear. Although some retrospective studies reported an
increased risk of fetal malformations in pregnant women
using aspirinduringﬁrst months, prospectivestudiesdidnot
conﬁrmed this result.
A meta-analysis of eight studies (seven observational
and one randomized) evaluated whether aspirin use during
the ﬁrst trimester of pregnancy is associated with an
increased risk of congenital malformations and found no
evidence of an overall increase in rates of major congenital
malformations, suggesting that aspirin is safe even when
used early in pregnancy [66]. This analysis, however, showed
that exposure to aspirin may be associated with an increased
risk of gastroschisis, but the reliability of this result should
be biased because of the limitations of the studies involved
related to the use of other drugs, the selection of controlStroke Research and Treatment 9
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subjects, and failure to deﬁnitively conﬁrm the diagnosis in
all patients [66]. Potential complications of aspirin therapy
in late pregnancy include fetal and maternal bleeding,
premature closure of the ductus arteriosus, prolongation of
labour, and delay in the onset of labor. According to data
reported in another meta-analysis of 14 randomized studies
including a total of 12,416 women, there is no evidence
of fetal and maternal adverse eﬀects of low-dose aspirin
therapy (60 to 150mg/d) administered during the second
and the third trimester of pregnancy in women at risk for
pre-eclampsia [67].
Therefore, available evidence suggests that low-dose
aspirin (<150mg/die) can be used safely during the second
and third trimester; by contrast, the safety of higher dose of
aspirin and/or aspirin ingestion during the ﬁrst trimester is
controversial.
Clopidogrel has not been found to cause signiﬁcant feto-
toxicity in animal studies at high doses, but there are no
adequate and well-controlled studies in pregnant women
so far. Only few case reported pregnant women who had
successful outcome while taking clopidogrel [68, 69]. Thus,
there are insuﬃcient data to evaluate its safety in this setting.
Although dipyridamole has not been found to cause
signiﬁcant fetal adverse eﬀects, there are no adequate data
regarding safety or eﬀectiveness of dipyridamole in humans
during pregnancy.
8.4. Thrombolytic Treatment. No data are available about
the use of thrombolytic treatment in pregnancy since this
conditions was an exclusion criteria from clinical trials that
validated these therapies. To date, the experience is limited
only to case reports and case series, including diﬀerent
thromboembolic conditions such as pulmonary embolism,
thrombosis of cardiac valve prosthesis, myocardial infarcts,
and deep venous thrombosis, but also ischemic stroke [70].
Due to its large molecular size, recombinant human tissue
plasminogen activator (rt-PA) does not cross the placental
barrier and studies on animal model have not shown
teratogenic eﬀects [71, 72]. However, fetal adverse eﬀects
remain largely unknown. Obstetric concerns are also raised
by the possible eﬀects on the placenta resulting in premature
labor, placental abruption, or fetal demise.
In the last years, thrombolysis for acute ischemic stroke
in pregnancy has been described in only 11 patients [70, 73–
77]( Table 4). In most cases, patients received thrombolysis
during the ﬁrst trimester, sometimes inadvertently. One
of six patient treated with systemic rt-PA died; the other
ﬁve women were treated with catheter-based therapy (three
intra-arterial rt-PA, one intra-arterial urokinase, and one
local urokinase). Four patients did not have complications,
while three had cerebral hemorrhage with clinical worsening
in one case. Hemorrhagic complications also included
intrauterine hematoma in one case and buttock hematoma
in another one. Two women had an elective therapeutic
abortion and one a spontaneous miscarriage.
Moreover, thrombolysis in the postpartum period was
also reported, within ﬁfteen hours after a cesarean delivery
in one case and after six days from delivery in another one,
without complications for the patients [78, 79].
However, because of the diﬀerences in etiologies, as well
as in thrombolytic agents used and in the way of admin-
istration, it is diﬃcult to draw any conclusion regarding
safety or eﬀectiveness although favorable maternal outcome
was shown in many cases. Therefore, thrombolytic therapy
should not be withheld for potentially disabling stroke dur-
ing pregnancy, butin each clinicalsituation, since experience
is limited, the ultimate choice of therapies must be based
on careful assessment of the maternal and fetal risks and
beneﬁts.
9.Prognosis and Recurrence
In a previous study of late sixties, the maternal mortality
immediately after stroke was reported to be 26% [8]. Subse-
quently, maternal mortality following cerebral infarction has
been reported not to exceed 14% and some studies reported
no maternal deaths secondary to an ischemic stroke [7, 14].
However, a reliable estimate is diﬃcult as a consequence
of small number of events and diﬀerent characteristic of
published studies (Table 2).
In the Ile de France study, about half of the patients
had a mild to moderate residual neurological deﬁcit, with
a modiﬁed Rankin score raging from 1 (3 patients) to 2 (2
patients) [7]. Skidmore and coworkers reported that 73%
of the patients were discharged home [15]. Fetal outcome
showed a death rate of about 12% [7].
Data regarding the inﬂuence of pregnancy on the risk
of recurrent stroke are scarce, thereby making diﬃcult to
counsel women with a history of ischemic stroke about
future pregnancies.
AmulticenterFrenchstudyonagroupof489consecutive
women aged 15 to 40 years with a ﬁrst-ever arterial ischemic
stroke or cerebral venous thrombosis showed that the risk
of stroke recurrence associated with subsequent pregnancies
is relatively small [80]. In this study, twenty-eight patients
(of 373 with arterial ischemic stroke) had the initial ischemic
event during pregnancy or the puerperium. During a mean
followup period of 5 years, 13 of the whole cohort had
a recurrent stroke but only two of these occurred in a
subsequent pregnancy, related to rare deﬁnite causes of
stroke such as essential thrombocythemia and primary
antiphospholipid syndrome. No woman whose initial stroke
occurred during pregnancy had a recurrent stroke during
subsequent pregnancies. The postpartum period, not the
pregnancy itself, is associated with an increased risk of
recurrentstroke(RR9.68,95%CI1.2,78.9),buttheseresults
may be limited by small number of observed events, lack
of prospective record of recurrent events and subsequent
pregnancies, and by a selection bias related to follow-up lost.
In line with these results, a descriptive study of a series
of 23 patients with a history of a previous ischemic stroke
showed no recurrence of ischemic stroke during subsequent
pregnancy or after delivery [81].
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